4.7 Article

Discovering new peripheral plasma biomarkers to identify cognitive decline in type 2 diabetes

Journal

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2022.818141

Keywords

type 2 diabetes; mild cognitive impairment; Alzheimer's disease; diagnostic biomarkers; proteomics

Funding

  1. Science and Technology Committee of China [2016YFC1305800]
  2. Natural Science Foundation of China [91949205, 31730035, 81721005, 81901107]
  3. Hubei Province [2018ACA142, WJ 2021M041]
  4. Wuhan Health Science Foundation [WX20Q04]
  5. Guangdong Provincial Key ST Program [2018B030336001]
  6. Fundamental Innovative Research Funds [HUST. 500351010]

Ask authors/readers for more resources

This study identified differentially expressed proteins in T2DM-MCI patients compared to T2DM-nMCI patients using proteomics analysis. These proteins were enriched in several biological processes and showed strong correlation with high-risk genes for Alzheimer's disease. Furthermore, the levels of some proteins were correlated with cognitive impairment score and machine learning data showed that certain proteins had the greatest power to identify mild cognitive decline in T2DM patients.
Type 2 diabetes mellitus (T2DM) is an independent risk factor of Alzheimer's disease (AD), and thus identifying who among the increasing T2DM populations may develop into AD is important for early intervention. By using TMT-labeling coupled high-throughput mass spectrometry, we conducted a comprehensive plasma proteomic analysis in none-T2DM people (Ctrl, n = 30), and the age-/sex-matched T2DM patients with mild cognitive impairment (T2DM-MCI, n = 30) or T2DM without MCI (T2DM-nMCI, n = 25). The candidate biomarkers identified by proteomics and bioinformatics analyses were verified by ELISA, and their diagnostic capabilities were evaluated with machine learning. A total of 53 differentially expressed proteins (DEPs) were identified in T2DM-MCI compared with T2DM-nMCI patients. These DEPs were significantly enriched in multiple biological processes, such as amyloid neuropathies, CNS disorders, and metabolic acidosis. Among the DEPs, alpha-1-antitrypsin (SERPINA1), major viral protein (PRNP), and valosin-containing protein (VCP) showed strong correlation with AD high-risk genes APP, MAPT, APOE, PSEN1, and PSEN2. Also, the levels of PP2A cancer inhibitor (CIP2A), PRNP, corticotropin-releasing factor-binding protein (CRHBP) were significantly increased, while the level of VCP was decreased in T2DM-MCI patients compared with that of the T2DM-nMCI, and these changes were correlated with the Mini-Mental State Examination (MMSE) score. Further machine learning data showed that increases in PRNP, CRHBP, VCP, and rGSK-3 beta(T/S9) (ratio of total to serine-9-phosphorylated glycogen synthase kinase-3 beta) had the greatest power to identify mild cognitive decline in T2DM patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available